ArticleCureus2025
Therapeutic Challenges in Metastatic Myxofibrosarcoma: A Case-Based Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myxofibrosarcoma (MFS) is a histologically distinct and aggressive subtype of soft tissue sarcoma, most often affecting elderly individuals and commonly presenting in the extremities. Despite standard treatment modalities, including surgical resection, radiotherapy, and chemotherapy, MFS is notable for its high recurrence and metastatic potential. We present the case of a 64-year-old woman with stage IIIA MFS of the right thigh and progressive pulmonary metastases, despite undergoing radiotherapy, surgery, and systemic chemotherapy. Her disease course was complicated by genetic alterations, including NF1 and ATM mutations, suggesting potential responsiveness to targeted therapies such as MEK and PARP inhibitors. Histological and immunohistochemical findings confirmed a fibrohistiocytic origin, consistent with metastatic MFS. This case highlights the diagnostic and therapeutic challenges associated with MFS, emphasizing the need for improved molecular characterization and novel therapeutic strategies. While current treatments provide limited durable control, emerging insights into the tumor's genetic and immune landscape offer hope for more effective, personalized approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.